Nearly two decades ago, during a business trip to K Hospital (Hanoi), Nguyen Van Qua, former general director of Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar), witnessed the plight of two women whose relatives were undergoing cancer treatment. The cost of medication, reaching hundreds of millions of dong per treatment, coupled with living expenses during the treatment period, posed a significant burden. At the time, cancer drugs had to be imported, making treatment costs beyond the reach of most patients.
Driven by this concern, in 2008, Nguyen Van Qua and Bidiphar's team of experts and pharmacists initiated a project to research and produce cancer drugs in Vietnam. In 2010, Bidiphar's first cancer drug received marketing authorization from the Ministry of Health. Building on this foundation, the company was entrusted by the state to implement several national-level projects and initiatives related to cancer drugs. Notable among these is the scientific project "Research, development, and application of technology to produce several cancer drugs at Bidiphar," with a total investment of 250 billion dong, making Bidiphar one of the first companies to successfully produce cancer drugs domestically.
 |
Bidiphar's pharmacists researching products. Photo: Bidiphar |
Bidiphar's pharmacists researching products. Photo: Bidiphar
Bidiphar is now a leading domestic producer of cancer drugs. This success has enabled Vietnamese cancer patients to access quality treatment at reasonable prices. People's Doctor, general director Pham Thi Thanh Huong, representing Bidiphar, stated, "The success of the cancer drug project is not only an achievement for the company but also a testament to the self-reliance of the Vietnamese pharmaceutical industry in its journey of integration and development,".
In 2023, Bidiphar inaugurated its high-tech pharmaceutical production plant in Nhon Hoi Economic Zone (Gia Lai), with a total investment of over 400 billion dong. Here, cancer drugs are manufactured according to GMP-EU standards, the most stringent European standards. This milestone further affirms Bidiphar's capability to bring "made in Vietnam" pharmaceutical products to the international stage.
 |
Bidiphar inaugurates a cancer drug production plant in 2023. Photo: Bidiphar |
Bidiphar inaugurates a cancer drug production plant in 2023. Photo: Bidiphar
Alongside its research and production mission, Bidiphar recognizes social responsibility as an integral part of its sustainable development strategy. This commitment is demonstrated through consistent actions, from over two decades of supporting kidney patients and over 15 years of assisting cancer patients, to participating in relief efforts for those affected by floods and promoting community health.
In particular, the project to develop GACP-WHO standard clean medicinal herb farms in Gia Lai exemplifies the company's long-term vision. This project contributes to the preservation of valuable medicinal gene sources while creating sustainable livelihoods for people in the highlands.
"The 45-year milestone is a testament to a journey of dedication and also a driving force for Bidiphar to continue contributing to the goal of building a self-reliant and sustainable Vietnamese healthcare system," a company representative said.
Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar) is a company with 45 years of development, honored as a National Brand in 2022 and ranked among the top 5 reputable pharmaceutical companies in 2023. The company owns numerous international GMP-WHO standard production lines and pioneers in research and application of advanced technology in management, production, and business. The company successfully researched and produced injectable antibiotics (1992), antibiotic-vitamin-amino acid infusion solutions (1997), freeze-dried injections (2003), and notably, cancer drugs (2008). With the vision of being in the top 5 by 2026 and top 3 Vietnamese pharmaceutical companies by 2030, Bidiphar remains committed to its mission of "caring for health - sharing joy," creating high-quality products and services, and contributing to improving community health.
The Dan
